Sally C
Fri Feb 10, 2012, 09:48 AM
From the MDS Beacon...
Clinical Trial Results Reveal Safety Issues With Nplate In Lower-Risk MDS Patients (ASH 2011)
by Linda Vuong and Maike Haehle
Results of a recent clinical trial show that lower-risk myelodysplastic syndromes patients treated with Nplate have fewer bleeding problems, require fewer platelet transfusions, and are more likely to have increased platelet counts than patients treated with a placebo.
However, the trial investigators also found transient increases in immature blood cell counts and a higher risk for progression to acute myeloid leukemia in patients treated with Nplate.
For the rest, see the article at MDS Beacon (http://www.mdsbeacon.com/news/2012/02/09/nplate-romiplostim-safety-myelodysplastic-syndromes-mds-ash-2011/).
Clinical Trial Results Reveal Safety Issues With Nplate In Lower-Risk MDS Patients (ASH 2011)
by Linda Vuong and Maike Haehle
Results of a recent clinical trial show that lower-risk myelodysplastic syndromes patients treated with Nplate have fewer bleeding problems, require fewer platelet transfusions, and are more likely to have increased platelet counts than patients treated with a placebo.
However, the trial investigators also found transient increases in immature blood cell counts and a higher risk for progression to acute myeloid leukemia in patients treated with Nplate.
For the rest, see the article at MDS Beacon (http://www.mdsbeacon.com/news/2012/02/09/nplate-romiplostim-safety-myelodysplastic-syndromes-mds-ash-2011/).